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Abstract
Recent genome-wide association studies have identified numerous loci associated with neuropsychiatric disorders.
The majority of these are in non-coding regions, and are commonly assigned to the nearest gene along the genome.
However, this approach neglects the three-dimensional organisation of the genome, and the fact that the genome contains
arrays of extremely conserved non-coding elements termed genomic regulatory blocks (GRBs), which can be utilized to
detect genes under long-range developmental regulation. Here we review a GRB-based approach to assign loci in non-
coding regions to potential target genes, and apply it to reanalyse the results of one of the largest schizophrenia GWAS
(SWG PGC, 2014). We further apply this approach to GWAS data from two related neuropsychiatric disorders—autism
spectrum disorder and bipolar disorder—to show that it is applicable to developmental disorders in general. We find that
disease-associated SNPs are overrepresented in GRBs and that the GRB model is a powerful tool for linking these SNPs to
their correct target genes under long-range regulation. Our analysis identifies novel genes not previously implicated in
schizophrenia and corroborates a number of predicted targets from the original study. The results are available as an online
resource in which the genomic context and the strength of enhancer–promoter associations can be browsed for each
schizophrenia-associated SNP.
Introduction
The primary aim of genome-wide association studies
(GWAS) and other genetic association studies is arguably to
serve as the first step in elucidation of the biological
mechanisms responsible for the onset of disease, which will
eventually lead to their translation into clinical practice.
While GWAS and other genetic association studies have
made great steps towards understanding many diseases,
progress has so far fallen short of initial expectations for
most neuropsychiatric disorders. This is primarily due to the
difficulty of identifying the biological effect of variants
identified as significantly associated with the disorder. More
philosophically, it is becoming increasingly recognised that
considering interactions across the whole system is required
to understand mechanisms in biology [1], and this may be
particularly the case for brain disorders [2]. In the rest of the
article we will refer to GWAS because they are the focus of
much genetic research in neuropsychiatric disorders at the
moment, but the same issues apply to other genetic asso-
ciation studies.
The GWAS approach attempts to identify the statistically
significant overrepresentation of specific single-nucleotide
polymorphism (SNP) alleles in a group of affected indivi-
duals vs. a healthy control group. This is performed for a
panel of hundreds of thousands of SNPs, selected such that
they “tag” each linkage disequilibrium (LD) block across
the genome at least once. Due to the LD structure of the
genome, each identified variant will have hundreds to
thousands of other variants in its proximity that are also
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significantly associated with the trait. The first stumbling
block when interpreting GWAS results is thus the identifi-
cation of the causal variant responsible for the statistical
association of the tagged SNP and the trait being studied.
The identification of the variant that underlies the biological
effect responsible for the statistical association with the
disease is known as fine mapping (reviewed in [3]). This
procedure is highly dependent on the quality of genotyped
data used for the reference (relatively large LD blocks
present in the European population were historically espe-
cially problematic [4]), the size of the GWAS sample and
the concordance of variant quality control across studies
used [5], with notable recent success by Mahajan et al. [6]
and others [7, 8].
Even with knowledge of the exact causal variant
responsible for a GWAS hit, there is often significant
difficulty in identifying its biological effect, particularly in
the case of non-coding SNPs. In the catalogue of published
GWAS, ~95% of the ~47,000 identified SNPs (as of April
2018) fall in non-coding regions of the genome, and are
enriched in regulatory elements [9, 10]. In many cases the
identified variants fall within gene deserts, potentially
millions of base pairs away from the closest gene. This
makes interpreting their biological effect very difficult.
Historically, the most prevalent practice in the literature is
to assign a non-coding variant’s effect to the closest
gene in terms of genomic distance. However, this approach
neglects the three-dimensional structure of the
genome, and fails to consider that many genes are subject
to long-range regulation by enhancers up to a megabase
away from their transcription start site, discussed in more
detail in Box 1. This is often the case for developmental
genes such as SHH [11], MYC [12] and SOX9 [13], many
of which are relevant to neuropsychiatric disorders. In
each of these cases enhancers loop over large genomic
distances to contact the promoter of their target gene, even
in the presence of intervening genes (Fig. 1a). Thus,
assigning SNPs that are part of regulatory elements to the
genes nearest to their loci means their more distant targets
may be missed and the wrong genes can end up being
investigated for disease mechanism. These long-range
regulatory elements are often grouped together on chro-
mosomes in arrays known as genomic regulatory blocks
(GRBs) [14–16]. GRBs have particular characteristics that
can be used to identify them and their targets (see Box 1
for more details).
Ragvin et al. have applied the GRB model to success-
fully determine the regulatory targets of non-coding SNPs
associated with type 2 diabetes and obesity [17]. For
example, they re-examined an SNP initially linked to the
FTO gene. Using the extent of non-coding conservation and
the GRB boundaries between humans and zebrafish, the
authors were able to predict the correct regulatory targets of
conserved non-coding elements (CNEs) spanning the
GWAS implicated LD blocks for three loci, leading to
predictions that the SNP in the FTO region disrupted a
conserved motif regulating IRX3 (Fig. 1). These predictions
were validated by transgenic reporter assays and implicated
Box 1
Some of the best known examples of regulatory elements acting on genes across extreme distances include key developmental genes such as
SHH [11], MYC [12] and SOX9 [13] (Fig. 1a). Each of these cases serves to illustrate that enhancers can loop over large genomic distances to
contact the promoter of their target gene, even in the presence of intervening genes.
In many cases the regulatory regions of genes under the control of long-range regulation coincide with clusters of extreme non-coding
conservation [17]. These conserved non-coding elements (CNEs) are long stretches of non-coding DNA, which are deeply conserved in
vertebrates [68–70] and function as enhancer elements, driving complex spatiotemporal gene expression patterns [70–72]. The requirement for
regulatory elements to remain in cis with the gene that they regulate [73] has constrained the organization of the genome, resulting in long
syntenic arrays of CNEs clustered around genes involved in the regulation of development [14, 15, 69]. These syntenic arrays, known as
genomic regulatory blocks (GRBs), can be used to delimit the boundaries beyond which it is unlikely a non-coding SNP may have an effect on
gene expression (Fig. 1b). Furthermore, each GRB tends to target a single gene or a few related genes, distinguishable from bystander genes in
promoter structure, specific patterns of epigenetic modifications, tissue specificity and range of biological functions [16] (Fig. 1c).
Since the original detection of GRBs and the specific features of their target genes [16], a more robust, fully automated method for GRB and
target gene prediction has been developed (Tan and Lenhard, in preparation, and Supplementary Methods). Briefly, GRBs are detected as
clusters of conserved synteny occurring at a higher rate than expected for the two genomes compared (here: human vs. mouse), excluding those
GRBs that do not overlap a protein-coding gene. A total of 1072 genomic regulatory blocks have been detected in this manner, spanning
between 28 kb and 5.35 Mb in length (mean 882 kb). Next, all genes in GRBs are given a target prediction value, based on a random
forest model trained on a set of target genes from Akalin et al., using a range of features that are the strongest indicators of genes amenable to
long-range regulation, i.e. length of CpG islands, gene entropy and CNE density (for more details, check Supplementary Methods). Using a
simple cut-off on the score that has been normalised within each GRB, all genes spanning a GRB are then classified either as bystanders or
targets.
Several GWAS detected disease-associated variants within introns of bystanders in GRBs, where the disease phenotype fitted well with loss of
function of the target gene, were reviewed by Becker and Rinkwitz [74], and references therein), arguing for these non-coding variants being
involved in regulation of the GRB target genes. In particular, they provide the GRB context for the intronic SNPs in ELP4 (a bystander gene, a
target is PAX6) linked to aniridia; SNPs in the bystander LMBR (with target SHH a megabase away) causing preaxial polydactyly; again SOX4
being targeted by intronic SNPs in CDKAL1 and IRX3 being targeted by SNPs in introns of the FTO, both associated with type 2 diabetes; and
implicate intergenic SNPs between two bystanders to be misregulating MEIS2, ultimately leading to myopia.
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Fig. 1 Long-range gene regulation. a An enhancer can target a gene
over large genomic distances. b A genomic regulatory block (GRB)
spanning a 1.9Mb region of the human genome. This region displays
high levels of non-coding conservation between the human and four
vertebrate genomes, reflecting evolution over ~435 million years.
The non-coding conservation peaks around IRX3, the predicted target
gene in this GRB. The black vertical line and blue rectangle mark
the genomic position of the obesity-associated SNPs (rs1421085 and
rs9939609) from the Ragvin et al. study, and the linkage
disequilibrium block around it, respectively. Each SNP falls within an
enhancer that is capable of activating the expression of the IRX3 gene,
shown in red. c The GRB model: conserved non-coding elements
(shown in green) within a GRB contact the target gene’s promoter
(shown in red) through looping and regulate its transcriptional activity
in multiple contexts. SNPs in the linkage disequilibrium with reg-
ulatory elements involved in long-range gene regulation are often
erroneously assigned to the nearest bystander gene, associating the
wrong gene to the disease phenotype
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IRX3 in the development of type 2 diabetes and obesity for
the first time. The mechanism underlying the link between
IRX3 and these conditions was since established using both
4-C and CRISPR-Cas9 based methods, which showed that
the SNP in the FTO region de-repressed IRX3 expression,
leading to altered energy metabolism and increased lipid
storage [18, 19]. This illustrates the potential value of the
GRB model in identifying the targets of non-coding SNPs
found to be associated with a disorder in a GWAS.
Recently, the complexity of the gene regulation has
become more broadly appreciated [20, 21], and there have
been efforts to look beyond the closest gene and at the
broader genomic context of the locus to identify the target
gene affected by the variant [8, 22–24]. They potentially
affected genomic region around the SNP encompassing all
genes to be tested for the effect is generally defined in two
main ways: (i) by setting a fixed distance around every SNP
[24–26], typically 0.5–1Mb (in extreme case 2Mb) region
upstream and downstream of the disease-associated variant,
or (ii) using topologically associated domains (TADs),
which are based on prior chromatin interaction experiments
[27]. The former approach uses no additional information,
therefore making no assumption on which locus is likely to
be involved in long-range genomic interactions and thus
considers all genes within a set distance around every locus.
The search space for the target gene(s) is consequently
large, which increases the information load and the potential
for false positives or negatives. In addition, the set distance
is arbitrarily defined. In contrast, the second approach uses
experimentally determined topologically associated
domains to define the search space, based on the functional
assumption that interactions between an enhancer and a
promoter do not cross TAD boundaries. However, this
approach will still evaluate every enhancer–promoter pair as
equally plausible, while the GRB model approach identifies
the most likely target gene of the long-range regulation in
every block.
TADs are units of 3D genome structure that are
megabase-sized in mammalian genomes, and mostly
invariant across cell types and to a large extent across
species [28]. TADs delineate regions that preferentially
interact with themselves over other regions of the genome;
in other words, the vast majority of genomic interactions
start and end within the same TAD. Recently, several cases
where the disruption of TADs results in the emergence of
disease phenotypes have been identified. For example,
disruption of TADs has been shown to be responsible for
introducing de novo enhancer–promoter interactions,
resulting in the mis-regulation of gene expression during
limb development [29], for erroneous activation of proto-
oncogenes causing acute lymphoblastic leukaemia [30] and
finally TAD data in the developing brain shed new light on
the neurodevelopmental disorders [27].
In addition, a large effort has been made to map the
interactions between active promoters and the rest of the
genome in many tissues and cell types, for example
revealing tissue-specific aspects of genome architecture
in hematopoiesis [31]. However, TAD identification from
Hi-C data both necessitates a significant amount of starting
material, which is often not available for neuropsychiatric
disorders due to limited availability of biological material
from human brains, and incurs large sequencing costs due
to the depth required to sufficiently cover the spatio-
temporal complexity of gene regulation, especially in
human genome.
It has been recently shown that most TADs correlate well
with the span of GRBs: the boundaries of TADs are well
predicted by the boundaries of high density of conserved
non-coding elements in GRBs, arguing that these are two
manifestations of the same underlying regulatory phenom-
enon [32]. Thus, the GRB approach discussed above could
also help identify gene targets linked to the structural
organisation of the genome without the material require-
ments or costs of Hi-C. An additional advantage of the GRB
model is the ability to provide a tissue-invariant classifica-
tion value of how likely the gene is to be subjected to long-
range regulation for all the genes found within the GRB,
thus significantly narrowing the search space for targets of
SNPs involved in long-range regulation.
In the next section, we illustrate the potential use of
the GRB approach combined with functional enhancer
activity and gene expression data to inform the inter-
pretation of genetic association studies using the example
of schizophrenia.
Application of the GRB model sheds new
light on schizophrenia-associated loci
Schizophrenia is a severe mental disorder that is among the
leading causes of global disease burden, with a lifetime
prevalence of 0.7% [33–35]. It is a highly heritable neuro-
developmental disorder, but its genetic basis remains elu-
sive [36–39]. It is thought to be caused by the complex
interaction between inherited genetic predisposition and
environmental risk factors [39–41]; see Box 2 for a dis-
cussion on heritability estimates and detectable proportion.
In 2014, Schizophrenia Working Group of the Psychiatric
Genomics Consortium performed a large multi-stage schi-
zophrenia GWAS of 36,989 cases and 113,075 controls
[42], further referred to as the PGC GWAS dataset. One
hundred twenty-eight SNPs statistically associated with
schizophrenia were identified. These 128 SNPs were then
merged based on LD resulting in 108 loci, 83 of which had
never been implicated in schizophrenia before. Possible
targets for the non-coding SNPs were then assigned to the
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closest gene, or all genes that fell within a locus. This set of
loci provides the ideal dataset to illustrate the potential of
the GRB model to provide further insights into variants in
non-coding regions.
We identified GRBs based on conserved synteny
between human and mouse and overlapped these GRBs
with the 108 schizophrenia-associated loci identified by the
PGC. In total 52 of the 108 loci overlapped a GRB, with
four GRBs each overlapping two schizophrenia-associated
loci. For each locus, we compared the target genes proposed
by the original GWAS with the target gene for that GRB.
The aim was not to invalidate the gene list proposed in the
PGC study, but rather to identify additional, potentially
more plausible target genes for loci that are not trivial to
interpret. All 108 schizophrenia loci are summarised with
regard to GRB overlap and GWAS-associated and GRB-
associated target genes in Supplementary Table S1. In short,
we found that our GRB-based approach pointed to at least
one target gene originally mentioned in the PGC dataset for
25 schizophrenia-associated loci, while for the remaining 27
loci that overlapped GRBs an altogether different target was
predicted (Table 1). In total, our method predicts 120 genes
to be under long-range regulation in GRBs overlapping
schizophrenia-associated loci.
We applied the same approach to the recent GWAS for
autism and bipolar disorder, two other neuropsychiatric
disorders with high heritability (Box 2). This analysis shows
significant enrichment for the GWAS loci to overlap with
GRBs in autism (p < 0.05) but not bipolar disorder (p > 0.9;
Fig. 2b). In autism 82 of the 180 loci overlap a GRB, and
the GRB-based analysis indicates different gene targets than
those originally assigned for 61 of these loci (Fig. 2a). Thus,
the GRB method could help identify novel gene targets
from the GWAS studies of a number of neuropsychiatric
disorders, although potentially not for bipolar disorder.
While both the vicinity of the non-coding SNP to a gene,
and the GRB target gene prediction approach provide one or
more putative genes through which a non-coding SNP may
contribute to disease emergence, neither should be used as a
definitive argument for the gene to be considered the SNP
target. We appreciate that it would be informative to con-
sider the effect of SNPs on all the genes within a GRB/
TAD, but since the experimental validation of each
enhancer–promoter pair is prohibitively expensive in terms
of experimental time and resources, it is useful to focus on
the most likely targets first. Thus, we include an additional
metric of how responsive each of the candidate genes
(GWAS-proposed genes and GRB target genes) is to the
regulatory element(s) within disease-associated locus. The
FANTOM5 consortium produced cap analysis of gene
expression data (CAGE) for over a thousand human tissues
and cell lines, assaying the exact position and quantity of
transcription across the genome. The first advantage of this
dataset that make it particularly amenable to investigating
developmental aspects of schizophrenia is that unlike some
of the recent schizophrenia-associated RNA-seq datasets
(used in [23, 24]) and the GTEx project [43], FANTOM5
has transcriptional profiles of tissue, including neural tissue,
from 75 foetal and newborn subjects. Secondly, it was
found that enhancers undergo non-productive transcription
initiation in contexts in which they are active [44], making it
possible to capture the expression of a gene with the activity
of all of the enhancers in its vicinity using a single CAGE
experiment. For each GRB, we identify those genes whose
Box 2
Neurodevelopmental disorders like schizophrenia, autism and bipolar disorder display high heritability estimates, while at the same time
only a small fraction of this heritability can be recapitulated through genome-wide association studies [75]. More specifically, heritability
of schizophrenia has been estimated to be between 60% and 80% by large population-based studies and meta-analysis of twin studies [76, 77];
between 64% and 91% for autism by the most recent meta-analysis on twin studies [78] and between 60% and 80% for bipolar disorders
[79]. On the other hand, the SNP-based heritability estimated on liability scale has been estimated between 23% and 32% for schizophrenia
[52, 80, 81], 17% for autism and 25% for bipolar disorder [81].
This missing heritability may come from variants with smaller effect sizes thus far missed due to the sheer population size needed to achieve
statistical significance when testing for small effects [36], or other types of genetic variation, such as copy number variants [38, 82, 83]. The
GRB model is disease-agnostic and broadens the search space for target genes based on conserved synteny. This enables the detection of
previously unidentified target genes, thereby implicating novel gene families or mechanistic pathways. By searching the regions surrounding
other members of these enriched gene families or pathways for variants that appear suggestively associated but do not pass the genome-wide
significance threshold, it may be possible to resolve a portion of the missing heritability, while also identifying potential new therapeutic
targets.
While the rest of our analysis focuses exclusively on schizophrenia-associated variants, two additional recent datasets of SNPs associated with
other neurodevelopmental phenotypes, i.e. autism spectrum disorder (ASD) [84] and bipolar disorder (BD) [85], were checked for
overrepresentation in genomic regulatory blocks (Fig. 2). BD-associated loci showed no significant difference from propensity of a random
locus to fall in a genomic regulatory block, however, there was a marked increase in ASD-GWAS and SCZ-GWAS detected loci overlapping a
genomic regulatory block, indicating a role of genes involved in developmental transcription factors and/or cell adhesion, cell-cell signalling,
axon guidance genes (all are enriched among GRB target genes) in molecular mechanisms leading to autism and schizophrenia. It is worth
noting here that, since the BD-GWAS study is still in preprint form, no data on the LD blocks were available at the time of writing this analysis
and thus the LD block around each SNP was inferred (see Supplementary Methods); updating with actual LD blocks might potentially result in
under-/over-representation of BD loci in the GRBs.
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activity, across a wide panel of tissues and cell lines, cor-
relates best with the activity of its surrounding enhancers.
These are presumably the genes that are most responsive to
the activity of the enhancers and thus represent likely target
genes of GRB regulation. For putative enhancers that are in
high LD with schizophrenia-associated variants, this pro-
vides us with the most likely affected gene.
We have applied these methods to all loci across the gen-
ome. Here, we present four examples based on the analysis of
the schizophrenia loci, which serve to illustrate specific
situations in which considering variants in the GRB context is
particularly effective in either providing novel hypotheses or
refining existing ones. For the full analysis of the genomic
context and enhancer–promoter pair expression correlations
(for loci overlapping GRBs), and basic information on the
other loci detected in the schizophrenia GWAS [42], we
provide a Shiny [45] web app at http://scz.genereg.net/.
The GRB model provides alternative,
biologically plausible long-range targets
A notable example of an SNP involved in long-range reg-
ulation of gene expression is a locus obtained by merging
two SNPs in LD, with two nearby VRK2 and FANCL genes
highlighted as putative targets of these variants. Instead, we
propose an alternative target BCL11A: according to the
GRB model it is a preferred target for long-range regulation
by elements from this entire genomic region, including the
LD block spanning these two SNPs. BCL11A is implicated
in the aetiology of the schizophrenia [46], and the pheno-
types associated to SNPs in the same LD block fit with the
role of the BCL11A gene.
VRK2 encodes a serine/threonine kinase involved in
apoptosis and tumour cell growth signalling pathways. A
number of SNPs in the region of VRK2 have previously been
associated with schizophrenia, implicating it in the develop-
ment of the disease [47–49]. There is also evidence that whole
blood VRK2 mRNA levels are lower in schizophrenia patients
than healthy controls [48]. FANCL is an ubiquitin ligase,
involved in DNA repair. BCL11A is, however, implicated in
brain development, and the haploinsufficient mice display
cognition deficits and impaired social behaviour [50].
This locus is spanned by a GRB whose predicted target is
BCL11A: a developmental transcription factor essential for
cortical development (Fig. 3a). In fact, upon further reana-
lysis of the schizophrenia-associated variation [42], Basak
et al. found SNPs in the second intron of the BCL11A gene
with significance of association with schizophrenia just
missing the genome-wide cut-off at p= 1.52e−07 [46]. The
activity of enhancer elements Enh5–Enh8 are correlated
with the expression of VRK2, potentially through short-
range regulatory effects, but the dynamic range of the
VRK2′s response to enhancer activity is small (shown as the
change in median expression values between grey and
purple distributions in Fig. 3a). However, similar to the
Fig. 2 Long-range regulation in
neurodevelopmental GWAS
loci. a LD blocks that do not
overlap GRBs are shown in
grey. Loci in which the
predicted GRB target gene was
identified as schizophrenia
associated in the original GWAS
are shown in light red, and the
loci in which the GRB model
provides novel target gene
predictions are shown in dark
red. b The distribution of
overlaps with the genomic
regulatory blocks of the same
number of random regions.
P-value calculated based on
N= 10,000 randomisations
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example of the obesity linked discussed above [17], there is
also a strong positive correlation of elements Enh5–Enh8
with BCL11A transcription (despite a 2.5 Mb separation
between the gene and the regulatory elements). Due to the
extreme distance between this enhancer cluster and the
promoter of the BCL11A gene, this connection will be
missed by any of the methods relying on a fixed genomic
cut-off for the enhancer–promoter interactions, even in the
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most generous case presented in the recent schizophrenia
TWAS [23, 24] (max. distance of 500 kb), 2 Mb distance by
Huo et al. [26] and in a zebrafish phenotype atlas [25]. In
fact, both TWAS analyses reported FANCL as a significant
hit, but failed to further corroborate the link between this
locus and the FANCL by the Hi-C data [23], nor the gene
list analysis [24].
We propose a scenario in which the whole VRK/FANCL
region’s chromatin state differs between the two alleles,
which can be detectable in TWAS studies and as increased
transcriptional activity of the region with two SNPs in the
promoter region of the VRK2. However, both of these
genes are ubiquitously expressed across tissues, and have a
rather large baseline transcriptional activity: these are hall-
marks of GRB bystander genes, which are not dependent on
activation via long-range enhancers [16]. Moreover, the
association of another variant in the VRK2 promoter region,
rs2312147, with white matter volume in healthy subjects
[45], and white matter connectivity in schizophrenia
patients [47] implicates this locus in aberrant brain devel-
opment. Given BCL11A’s role in the regulation of neuronal
migration in the developing cortex, and in agreement with
the neural network hypothesis of schizophrenia aetiology
[38], we conclude that the evidence points to BCL11A
activation by this enhancer as the most likely biological
mechanisms responsible for the GWAS hits at this locus.
In this example, while there is evidence that VRK2 might
play a role in schizophrenia, the variant’s location adjacent
to Enh5–Enh8 region suggests that the enhancers in the
vicinity of the identified risk variants also regulates
BCL11A, with larger effect on its expression level than that
of VRK2. Therefore, the hypothesis-free annotation of GRB
targets has provided a more biologically plausible candidate
gene at this locus.
The GRB model predicts the potential
targets of unannotated SNPs
An advantage of the GRB model is that it provides an
unbiased, systematic list of target genes for all non-coding
SNPs within the GRB. This is illustrated by the LD block
chr2:146416922–146441832 harbouring a chr2_146436222_I
insertion located in a gene desert. This GRB spans the ZEB2,
GTDC1, ARHGAP15 and KYNU genes, with ARHGAP15 and
ZEB2 being the predicted targets of long-range regulation
(Fig. 3b). The expression of both predicted GRB target genes
is significantly correlated with the activity of the enhancer
overlapping this insertion. KYNU expression, which is not
found to be responsive to long-range regulation in this locus,
is also significantly correlated with the activity of the
enhancer. Despite this, the directionality index (which indi-
cates the start/end of a TAD [28]) in this region positions
KYNU outside of the TAD spanning ARHGAP15, ZEB2 and
the LD block with the significantly associated insertion,
supporting the GRB model target gene predictions.
ZEB2 encodes the zinc finger E-box binding protein and
is a key regulator of neurogenic and gliogenic processes
[51]. Heterozygous ZEB2 mutations in humans cause
Mowat–Wilson syndrome, often associated with structural
brain abnormalities and intellectual disability. Statistically
significant GWAS signals have been detected in three
smaller studies for the ZEB2 gene: in a 2013 PGC GWAS
study predating the dataset analysed here [52], in a Han
Chinese population GWAS from 2016 [53] and recently in
the GWAS meta-analysis including 40,675 schizophrenia
patients that included all the PGC patients, and additional
11,260 cases from the CLOZUK sample [8]. Taken toge-
ther, the link between ZEB2 and neurological development
and phenotypes makes ZEB2 a plausible candidate gene for
schizophrenia. On the other hand, mice mutants for the
ARHGAP15 gene showed cognitive deficits due to impaired
neuritogenesis in the hippocampus [54], and a de novo
synonymous mutation in this gene was found in a patient
with sporadic autism [55], followed by a recent report of a
chromatin interaction of a schizophrenia GWAS locus with
the promoter of the ARHGAP15 gene [8].
In this example, the GRB model provides us with two
novel, testable potential target genes for a schizophrenia-
associated variant, which originally had no associated
genes, and were confirmed by other GWAS datasets, and
subsequently by chromatin conformation data in post-
mortem brains.
The GRB model identifies mechanistically
related SNPs
The next example contains two schizophrenia-associated
loci that are both found in the same GRB
(chr11:130296827–133970287), and thus most likely affect
the same gene. As Fig. 3c shows, this GRB spans six genes,
three of which (NTM, OPCML and IGSF9B) are predicted
GRB targets. The PGC study proposes IGSF9B as the
Fig. 3 A schematic view of four genomic regulatory blocks. Arrows
represent genes, with their orientation indicated by the direction of the
arrow. The lower plot in each example is a matrix of log expression
values (in TPM) for each enhancer–promoter pair in that GRB. The
distribution of expression in tissues where the enhancer is inactive or
active is shown in grey and pink, respectively, and the number of
samples where each enhancer is (in)active is given under the enhancer
label. The black line represents the median expression for each dis-
tribution. Significant differences between the medians of the two
categories are marked with *p < 0.05, **p < 0.01 and ***p < 0.001
(permutation test, see Supplementary methods). Note, the schematics
are not to scale and merely represent gene order (for to-scale plots,
visit http://scz.genereg.net/)
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putative target of the rs75059851 SNP identified in the
original study due to the location of the SNP in the pro-
moter/first intron of two transcript isoforms of the IGSF9B.
The expression of all three of the predicted GRB target
genes is significantly greater in tissues in which the
enhancers are active, Fig. 2c. In this case all three predicted
target genes are neuronal specific cell adhesion molecules
involved in neuronal development and thus likely candidate
genes. Indeed, OPCML has been previously implicated in
the development of schizophrenia by multiple studies in
European [56] and Thai [57] populations. In addition,
increased levels of an NTM isoform have recently been
detected in the dorsolateral prefrontal cortex of schizo-
phrenia patients [58]. More importantly, the concordance of
putative enhancers in both schizophrenia-associated loci
with genes across the entire GRB (Fig. 3c), including
SNX19, supports the idea that variants rs10791097 (found
just downstream of, and originally thought to be a bystander
locus to SNX19 [42]) and rs75059851 share some
mechanistic aspects in the aetiology of the disease, and calls
for testing for effects of their interaction despite the large
genomic distance between them. This example highlights
how the GRBs can serve as functional units in which the
effects of multiple SNPs can be considered as potentially
interacting.
The unbiased prediction of GRB target genes
identifies potentially overlooked candidate
genes at well-studied loci
The final example is a locus that overlaps the gene for the
dopamine D2 receptor (DRD2)—the target of all licensed
antipsychotic therapy drugs [59]. The unpredictability of a
patient’s response to antipsychotic therapy, and alternative
roles of this locus have been under recent scrutiny [60]. This
locus overlaps a GRB containing both DRD2 and a neural
cell adhesion molecule gene, NCAM1, shown in Fig. 3d.
NCAM1 has previously been implicated in a number of
neuropsychiatric disorders, including schizophrenia [61],
and our analysis identifies NCAM1 as another plausible
target, despite not being categorized as a GRB target (it’s
predictive value is just below the threshold, see Supple-
mentary information). When active, the predicted enhancer
element in the schizophrenia-associated locus affects tran-
scription of both DRD2 and NCAM1, with a more promi-
nent effect on the transcription of the NCAM1 gene
(Supplementary Fig. 1). This locus illustrates the risk of
hypothesis-driven target gene search: once a gene, e.g.
DRD2, expected to play a role in disease aetiology is
identified, other putative targets in its vicinity may be
overlooked.
Lessons learned from application of the GRB
model to disease-associated genomic loci
Recent approaches to identifying pathways through which
non-coding variants lead to neuropsychiatric disorders such
as schizophrenia suffer from three major conceptual over-
simplifications. First and foremost, despite the wealth of the
literature published on complex modes of regulation
[17, 62], the practice of assigning non-coding variants to
nearby genes is still prevalent. The GRB model allows for
the expansion of the search for a target beyond adjacent
genes and provides boundaries as to which genes should be
included and which should not, but only in the cases where
GWAS loci occur in the region of the genome implicated in
the long-range regulation. Further, automated GRB target
gene prediction provides a shortlist of genes most likely to
be under the control of long-range regulation.
Next, epistatic effects between variants have been
reported for a range of human complex traits, however
systematic approaches to identify pairs of variants display-
ing epistatic effects suffers from multidimensionality pro-
blems and low reproducibility due to high false positive
rates (for a review see [63]). GRBs as functional regulatory
units may allow us to identify epistatic effects of non-
coding variants that fall within the same GRBs (as in the
NTM/OPCML/IGSF9B example in the Fig. 3c), as this
effectively reduces the number of statistical tests required
potentially allowing for the detection of modest epistatic
effects.
Finally, identification of target genes linked to a given
locus is often biased towards genes with functions and
pathways previously associated with the trait or disease
under investigation, potentially overlooking plausible
alternative hypotheses. The evolutionary nature of the GRB
model allows for an unbiased approach to identification of
potential target genes, potentially identifying novel target
genes and new disease mechanisms. Of particular interest is
a network of mutually interacting transcription factors
involved in neuronal development of cortical layers, pre-
dicted as targets in SCZ-GRBs: BCL11B, BCL11A, TBR1,
SATB2 and FEZF2 (Supplementary Fig. S2). Of these, only
BCL11B is listed among targets in the PGC study with
remainder not detected based on the assignment of non-
coding SNPs to the closest gene. GRBs often target genes
involved in development, which require complex regulation
[16]. Our finding that the non-coding genetic loci associated
with schizophrenia and autism, but not bipolar disorder, are
significantly more likely to occur in GRBs is thus consistent
with other evidence that there is a stronger neurodevelop-
mental component to these disorders than bipolar [64, 65],
and indicates novel potential developmental genes linked to
these disorders.
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Other schizophrenia GWAS datasets
Since the conception of this study, several smaller schizo-
phrenia GWAS datasets have emerged [8, 23, 24, 26, 27],
with many signals from the 2014 PGC study replicated, and
some new loci discovered. The most significant change in
these is a notable trend towards functional characterisation
of SNPs in view of finding regulatory variants using eQTL
information [8, 24, 26, 66], chromatin contacts [8, 27] and
transcription factor binding profiles [26]. We have analysed
the three largest datasets [8, 26, 67] in the same way as the
PGC GWAS represented here (Supplementary Fig. S3), and
showed that the GRB target gene prediction still implicates
many novel long-range contacts not documented in even the
most recent published data (Supplementary information and
Supplementary Tables S2 andS3). While a greater coverage
of high-resolution tissue-specific chromatin contacts, allele-
specific gene expression, transcriptome maps and genome-
wide binding profiles for a wider range of transcription
factors will partially close this gap in the future, the GRB
approach will stand as an elegant method of shortlisting (or
adding additional evidence for) genes through which reg-
ulatory non-coding variants exert their effects on disease
emergence.
Conclusions
The last few years have seen a step change in the power
of GWAS in neuropsychiatric disorders. This has led to
large numbers of novel loci being identified, but raises
a new challenge: determining the correct gene(s) linked
to these loci. The common practice of assigning non-
coding loci identified in GWAS to the nearest is likely to
be an oversimplification in a substantial proportion of
cases. In particular, it neglects the topological organisa-
tion of the genome, and the possibility that a locus may be
in, or linked to, a non-coding element that regulates a
distant gene. New understanding on the characteristics of
non-coding elements in highly conserved GRBs, and their
link to TADs can be used to identify the potential target
genes for loci in GRBs. We applied this knowledge to the
loci from recent GWAS in three neuropsychiatric dis-
orders, to show that for two of them, schizophrenia and
autism, there was an excess of loci located in GRBs than
would be expected by chance. Further analysis showed
the potential of this approach to identify novel plausible
genes for the schizophrenia, such as NTM, ARHGAP15
and ZEB2. This illustrates the potential value of the GRB
approach and the need to consider the role of non-coding
elements to guide the biological analysis of loci identified
by GWAS.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you
give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made. The images or other third party material in this article are included
in the article’s Creative Commons license, unless indicated otherwise in a
credit line to the material. If material is not included in the article’s
Creative Commons license and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Bechtel W. Mechanists must be holists too! perspectives from
circadian biology William. J Hist Biol. 2016;49:705–31. http://
philsci-archive.pitt.edu/12075/.
2. Bechtel W. Network Organization in Health and Disease: on being
a reductionist and a systems biologist too. Pharmacopsychiatry.
2013;46:10–21.
3. Spain SL, Barrett JC. Strategies for fine-mapping complex traits.
Hum Mol Genet. 2015;24:111–9.
4. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ,
et al. Link disequilibrium in the human genome. 2001;9:199–204.
5. Benner C, Havulinna AS, Jarvelin M-R, Salomaa V, Ripatti S,
Pirinen M. prospects of fine-mapping trait-associated genomic
regions by using summary statistics from genome-wide associa-
tion studies. Am J Hum Genet. 2017;101:539–51.
6. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM,
Rayner WN, et al. Fine-mapping type 2 diabetes loci to single-
variant resolution using high-density imputation and islet-specific
epigenome maps. Nat Genet. 2018;50:1505–13.
7. Lam M, Chen C, Li Z, Martin AR, Bryois J. Comparative genetic
architectures of schizophrenia in East Asian and European popula-
tions. 2018. https://www.biorxiv.org/content/10.1101/445874v2.
8. Pardinas AF, Holmans P, Pocklington AJ, Escott-Price V, Carrera
N, Legge SE, et al. Common schizophrenia alleles are enriched in
mutation- intolerant genes and in regions under strong background
selection. Nat Genet. 2018;50:381–9.
9. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M.
Linking disease associations with regulatory information in the
human genome. Genome Res. 2012;22:1748–59.
10. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E,
Wang H, et al. Systematic localization of common disease-
associate variation in regulatorty DNA. Science. 2012;337:1190–5.
11. Lettice LA, Heaney SJH, Purdie LA, Li L, Beer P De, Oostra BA,
et al. A long-range Shh enhancer regulates expression in the
developing limb and fin and is associated with preaxial poly-
dactyly. Hum Mol Genet. 2003;12:1725–35.
12. Sotelo J, Esposito D, Ana M, Ban K, Mehalko J, Liao H. Long-
range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci
USA. 2010;107:3001–5.
13. Bagheri-Fam S, Barrionuevo F, Dohrmann U, Günther T,
Schüle R, Kemler R, et al. Long-range upstream and downstream
16 A. Barešić et al.
enhancers control distinct subsets of the complex spatiotemporal
Sox9 expression pattern. Dev Biol. 2006;291:382–97.
14. Engström PG, Sui SJH, Drivenes Ø, Becker TS, Lenhard B.
Genomic regulatory blocks underlie extensive microsynteny
conservation in insects. Genome Res. 2007;17:1898–908.
15. Kikuta H, Laplante M, Navratilova P, Komisarczuk AZ, Engström
PG, Fredman D, et al. Genomic regulatory blocks encompass
multiple neighboring genes and maintain conserved synteny in
vertebrates. Genome Res. 2007;17:545–55.
16. Akalin A, Fredman D, Arner E, Dong X, Bryne JC, Suzuki H,
et al. Transcriptional features of genomic regulatory blocks.
Genome Biol. 2009;10:1–13.
17. Ragvin A, Moro E, Fredman D, Navratilova P, Drivenes O,
Engström PG, et al. Long-range gene regulation links genomic
type 2 diabetes and obesity risk regions to HHEX, SOX4, and
IRX3. PNAS. 2011;107:775–80. http://www.pnas.org/cgi/doi/10.
1073/pnas.1101890108.
18. Smemo S, Tena JJ, Kim K-H, Gamazon ER, Sakabe NJ, Gómez-
Marín C, et al. Obesity-associated variants within FTO form long-
range functional connections with IRX3. Nature. Nat Publ Gr.
2015;507:371–5. https://doi.org/10.1038/nature13138.
19. Claussnitzer M, Dankel SN, Kim K-H, Quon G, Meuleman W,
Haugen C, et al. FTO obesity variant circuitry and adipocyte
browning in humans. N Engl J Med. 2015;373:895–907.
20. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Func-
tional mapping and annotation of genetic associations with
FUMA. Nat Commun. 2017;8:1826. https://doi.org/10.1038/
s41467-017-01261-5.
21. Huang D, Yi X, Zhang S, Zheng Z, Wang P, Xuan C, et al.
GWAS4D: multidimensional analysis of context-specific reg-
ulatory variant for human complex diseases and traits. Nucleic
Acids Res. 2018;46:114–20.
22. Guo L, Wang J. RSNPBase 3.0: an updated database of SNP-related
regulatory elements, element-gene pairs and SNP-based gene reg-
ulatory networks. Nucleic Acids Res. 2018;46(D1):D1111–6.
23. Gusev A, Mancuso N, Finucane HK, Reshef Y, Song L, Safi A,
et al. Transcriptome-wide association study of schizophrenia and
chromatin activity yields mechanistic disease insights. Nat Genet .
2018;067355. https://doi.org/10.1101/067355.
24. Hall LS, Medway CW, Pardinas AF, Rees EG, Escott-price V,
Pocklington A, et al. A Transcriptome Wide Association Study
implicates specific pre- and post-synaptic abnormalities abnorm-
alities in Schizophrenia. 2018. https://www.biorxiv.org/content/
10.1101/384560v1.
25. Thyme SB, Pieper LM, Li EH, Pandey S, Wang Y, Morris NS, et al.
Phenotypic landscape of schizophrenia-associated genes defines
candidates and their shared functions. Cell. 2018;177:478–91.
26. Huo Y, Li S, Liu J, Li X, Luo X. Functional genomics reveal gene
regulatory mechanisms underlying schizophrenia risk. Nat Com-
mun. 2019;10. https://doi.org/10.1038/s41467-019-08666-4.
27. Won H, de la Torre-Ubieta L, Stein JL, Parikshak NN, Huang J,
Opland CK, et al. Chromosome conformation elucidates regulatory
relationships in developing human brain. Nature. 2016;538:523–7.
28. Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al.
Topological domains in mammalian genomes identified by ana-
lysis of chromatin interactions. Nature. 2012;485:376–80.
29. Lupiáñez DG, Kraft K, Heinrich V, Krawitz P, Klopocki E, Horn D,
et al. Disruptions of topological chromatin domains cause pathogenic
rewiring of gene-enhancer interactions. Cell. 2016;161:1012–25.
30. Hnisz D, Weintraub AS, Day DS, Valton A, Rasmus O, Li CH,
et al. Activation of proto-oncogenes by disruption of chromosome
neighborhoods. Science. 2016;351:1454–8.
31. Javierre BM, Sewitz S, Cairns J, Wingett SW, Várnai C, Thiecke
MJ, et al. Lineage-specific genome architecture links enhancers
and non-coding disease variants to target gene promoters. Cell.
2016;167:1369–.e19.
32. Harmston N, Ing-Simmons E, Tan G, Perry M, Merkenschlager
M, Lenhard B. Topologically associating domains are ancient
features that coincide with metazoan clusters of extreme non-
coding conservation. Nat Commun. 2017;8:441.
33. Saha S, Chant D, Welham J, Mcgrath J. A systematic review of
the prevalence of schizophrenia. PLoS Med. 2005;2:e141.
34. Mathers C, Boerma T, Fat D. The global burden of disease: 2004
update. 2008. http://www.who.int/healthinfo/global_burden_disea
se/2004_report_update/en/.
35. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ,
Erskine HE, et al. Global burden of disease attributable
to mental and substance use disorders: findings from the
Global Burden of Disease Study 2010. Lancet. 2013;382:
1575–86.
36. Kendler KS. What psychiatric genetics has taught us about the
nature of psychiatric illness and what is left to learn. Mol Psy-
chiatry. 2013;18:1058–66. https://doi.org/10.1038/mp.2013.50.
37. Howes OD, Murray RM. Schizophrenia: an integrated
sociodevelopmental-cognitive model. Lancet. 2014;383:1677–87.
https://doi.org/10.1016/S0140-6736(13)62036-X.
38. Singh S, Kumar A, Agarwal S, Phadke SR, Jaiswal Y. Genetic
insight of schizophrenia: past and future perspectives. Gene.
2014;535:97–100. https://doi.org/10.1016/j.gene.2013.09.110.
39. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O’Donovan
MC, et al. Evaluating historical candidate genes for schizophrenia.
Mol Psychiatry. 2015;20:555–62. http://www.nature.com/mp/
journal/v20/n5/full/mp201516a.html#tbl2.
40. Hall J, Trent S, Thomas KL, O’Donovan MC, Owen MJ. Genetic
risk for schizophrenia: convergence on synaptic pathways
involved in plasticity. Biol Psychiatry. 2015;77:52–8. https://doi.
org/10.1016/j.biopsych.2014.07.011.
41. Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of
genes, stress, and dopamine in the development of schizophrenia.
Biol Psychiatry. 2017;81:9–20. https://doi.org/10.1016/j.biopsych.
2016.07.014.
42. Consortium SWG of the PG. Biological insights from 108
schizophrenia-associated genetic loci. Nature. 2014;511:
421–7. https://doi.org/10.1038/nature13595.
43. Aguet F, Brown AA, Castel SE, Davis JR, He Y, Jo B, et al.
Genetic effects on gene expression across human tissues. Nature.
2017;550:204–13.
44. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J,
Boyd M, et al. An atlas of active enhancers across human cell
types and tissues. Nature. 2014;507:455–61. http://www.nature.
com/doifinder/10.1038/nature12787.
45. Chang W, Cheng J, Allaire J, Xie Y, McPherson J. shiny: web
application framework for R. R package version 1.0.0. 2017.
https://cran.r-project.org/package=shiny.
46. Basak A, Hancarova M, Ulirsch JC, Balci TB, Trkova M,
Pelisek M, et al. BCL11A deletions result in fetal hemoglobin
persistence and neurodevelopmental alterations. J Clin Investig.
2015;125:6–11.
47. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Hol-
mans PA, et al. Genome-wide association study identifies five new
schizophrenia loci. Nat Genet. 2011;43:969–78.
48. Li M, Wang Y, Bin ZhengX, Ikeda M, Iwata N, Luo XJ, et al.
Meta-analysis and brain imaging data support the involvement of
VRK2 (rs2312147) in schizophrenia susceptibility. Schizophr
Res. 2012;142:200–5.
49. Chang H, Zhang C, Xiao X, Pu X, Liu Z, Wu L, et al. Further
evidence of VRK2 rs2312147 associated with schizophrenia.
World J Biol Psychiatry. 2016;17:457–66.
50. Dias C, Estruch SB, Graham SA, Mcrae J, Sawiak SJ, Hurst JA,
et al. BCL11A haploinsufficiency causes an intellectual disability
syndrome and dysregulates transcription. Am J Hum Genet.
2016;99:253–74.
Understanding the genetics of neuropsychiatric disorders: the potential role of genomic regulatory blocks 17
51. Hegarty SV, Sullivan AM, O’Keeffe GW. Zeb2: a multifunctional
regulator of nervous system development. Prog Neurobiol.
2015;132:1–15. http://www.ncbi.nlm.nih.gov/pubmed/26193487.
52. Ripke S, Dushlaine CO, Chambert K, Moran JL, Anna K, Akterin
S, et al. Genome-wide association analysis identifies 13 new risk
loci for schizophrenia. Nature. 2013;45:1–26. http://www.nature.
com/ng/journal/v45/n10/abs/ng.2742.html.
53. Khan RAW, Chen J, Wang M, Li Z, Shen J, Wen Z, et al. A new
risk locus in the ZEB2 gene for schizophrenia in the Han Chinese
population. Prog Neuro-Psychopharmacol Biol Psychiatry.
2016;66:97–103. https://doi.org/10.1016/j.pnpbp.2015.12.001.
54. Zamboni V, Armentano M, Sarò G, Ciraolo E, Ghigo A, Germena
G, et al. Disruption of ArhGAP15 results in hyperactive Rac1,
affects the architecture and function of hippocampal inhibitory
neurons and causes cognitive deficits. Sci Rep 2016;October:1–17.
55. Roak BJO, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S,
et al. Exome sequencing in sporadic autism spectrum disorders
identifies severe de novo mutations. Nat Genet. 2011;43:585–9.
56. O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T,
Moskvina V, et al. Identification of loci associated with schizo-
phrenia by genome-wide association and follow-up. Nat Genet.
2008;40:1053–5.
57. Panichareon B, Nakayama K, Thurakitwannakarn W, Iwamoto S,
Sukhumsirichart W. OPCML gene as a schizophrenia suscept-
ibility locus in Thai population. J Mol Neurosci. 2012;46:373–7.
58. Karis K, Eskla K-L, Kaare M, Täht K, Tuusov J, Visnapuu T,
et al. Altered expression profile of IgLON family of neural cell
adhesion molecules in the dorsolateral prefrontal cortex of schi-
zophrenic patients. Front Mol Neurosci. 2018;11:1–12. http://
journal.frontiersin.org/article/10.3389/fnmol.2018.00008/full.
59. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S.
Mechanisms underlying psychosis and antipsychotic treatment
response in schizophrenia: insights from PET and SPECT ima-
ging. Curr Pharm Des. 2009;15:2550–9. http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3687204&tool=
pmcentrez&rendertype=abstract.
60. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD.
Dopamine synthesis capacity in patients with treatment-resistant
schizophrenia. Am J Psychiatry. 2012;169:1203–10. http://
psychiatryonline.org/doi/abs/10.1176/appi.ajp.2012.1201014.
61. Brennaman LH, Moss ML, Maness PF. EphrinA/EphA-induced
ectodomain shedding of neural cell adhesion molecule regulates
growth cone repulsion through ADAM10 metalloprotease. J
Neurochem. 2014;128:267–79.
62. Noonan JP, McCallion AS. Genomics of long-range regulatory
elements. Annu Rev Genomics Hum Genet. 2010;11:1–23.
http://www.annualreviews.org/doi/10.1146/annurev-genom-082509-
141651.
63. Wei W, Hemani G, Haley CS. Detecting epistasis in human
complex traits. Nat Rev Genet. Nat Pub Gr; 2014;15:722–33.
https://doi.org/10.1038/nrg3747.
64. Parellada M, Gomez-Vallejo S, Burdeus M, Arango C. Devel-
opmental differences between schizophrenia and bipolar disorder.
Schizophr Bull. 2017;43:1176–89.
65. Owen MJ, O’Donovan MC. Schizophrenia and the neurodeve-
lopmental continuum: evidence from genomics. World Psychiatry.
2017;16:227–35.
66. Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W,
Pardinas A, et al. Gene expression imputation across multiple
brain regions reveals schizophrenia risk throughout development.
2017. https://www.biorxiv.org/content/10.1101/222596v1.
67. Li Z, Chen J, Yu H, He L, Xu Y, Zhang D, et al. Genome-wide
association analysis identifies 30 new susceptibility loci for schi-
zophrenia. Nat Genet. 2017;49:1576–83.
68. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick
JS, et al. Ultraconserved elements in the human genome. Science.
2004;304:1321–5.
69. Sandelin A, Bailey P, Bruce S, Engström PG, Klos JM, Wasser-
man WW, et al. Developmental genes in vertebrate genomes.
BMC Genomics. 2004;9:1–9.
70. Woolfe A, Goodson M, Goode DK, Snell P, Mcewen GK,
Vavouri T, et al. Highly conserved non-coding sequences are
associated with vertebrate development. PLoS Biol. 2005;3:e7.
https://doi.org/10.1371/journal.pbio.0030007.
71. Bhatia S, Monahan J, Ravi V, Gautier P, Murdoch E, Brenner S,
et al. A survey of ancient conserved non-coding elements in the
PAX6 locus reveals a landscape of interdigitated cisregulatory
archipelagos. Dev Biol. 2014;387:214–28.
72. Navratilova P, Fredman D, Hawkins TA, Turner K,
Lenhard B, Becker TS. Systematic human/zebra fish compara-
tive identification of cis-regulatory activity around vertebrate
developmental transcription factor genes. Dev Biol. 2009;
327:526–40.
73. Ritter DI, Li Q, Kostka D, Pollard KS, Guo S, Chuang JH. The
importance of being cis: evolution of orthologous fish and mam-
malian enhancer activity. Mol Biol Evol. 2010;27:2322–32.
74. Becker TS, Rinkwitz S. Zebrafish as a genomics model for
human neurological and polygenic disorders. Dev Neurobiol.
2012;72:415–28.
75. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA,
Hunter DJ, et al. Finding the missing heritability of complex
diseases. Nature 2009;461:747–53.
76. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sulli-
van PF, et al. Common genetic determinants of schizophrenia and
bipolar disorder in Swedish families: a population-based study.
Lancet. 2009;373:234–9.
77. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex
trait. Arch Gen Psychiatry. 2003;60:1187–92.
78. Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F. Heritability of
autism spectrum disorders: a meta-analysis of twin studies. J Child
Psychol Psychiatry Allied Discip. 2016;57:585–95.
79. Nöthen MM, Nieratschker V, Cichon S, Rietschel M. New find-
ings in the genetics of major psychoses. Dialogues Clin Neurosci.
2010;12:85–93.
80. Lee S, DeCandia T, Ripke S, Yang J, (PGC-SCZ) SPG-WASC,
ISC, et al. Estimating the proportion of variation in susceptibility
to schizophrenia captured by common SNPs. Nat Genet. 2012;
44:247–50.
81. Smoller JW, Kendler K, Craddock N, Lee PH, Neale BM,
Nurnberger JN, et al. Identification of risk loci with shared effects
on five major psychiatric disorders: a genome-wide analysis.
Lancet. 2013;381:1371–9.
82. Grayton HM, Fernandes C, Rujescu D, Collier DA. Copy number
variations in neurodevelopmental disorders. Prog Neurobiol.
2012;99:81–91.
83. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental
model of schizophrenia: Update 2012. Mol Psychiatry. 2012;
17:1228–38.
84. Anney RJL, Ripke S, Anttila V, Grove J, Holmans P, Huang H,
et al. Meta-analysis of GWAS of over 16,000 individuals with
autism spectrum disorder highlights a novel locus at 10q24.32
and a significant overlap with schizophrenia. Mol Autism.
2017;8:1–17.
85. Stahl E, Forstner A, McQuillin A, Ripke S, PGC BDWG of
the, Ophoff R, et al. Genomewide association study identifies
30 loci associated with bipolar disorder. Nat Genet. 2019;
51:793–803.
18 A. Barešić et al.
